KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial.

Soo Lim, Tae Nyun Kim, Ji Oh Mok, Choon Hee Chung, You Cheol Hwang, Ho Chan Cho, Jong Chul Won, Eonju Jeon, Eun Seok Kang, Ki Young Lee, Chong Hwa Kim, Soo Heon Kwak, Cheol Young Park, Kang Seo Park, Sang Yong Kim, Jae Hyuk Lee, Soon Hee Lee, Dong Hyeok Cho, Hyuk-Sang Kwon, Kyung Ah Han

Diabetes Obes Metab 28(6) 4847-4859

PMID41883295
PMCIDPMC13146161
DOI10.1111/dom.70669
发表日期2026-03-26
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:AI 判定为 other。
摘要

摘要

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive, multi-organ disorder that often requires intensive combination therapy. This Phase III, randomised, double-blind, placebo-controlled study evaluated the efficacy and safety of two fixed-dose combinations (FDCs) of sitagliptin 100 mg with empagliflozin 10 mg (DW1026C1) or empagliflozin 25 mg (DW1026C2) as add-on therapy for patients with inadequately controlled T2DM. METHODS: Two hundred thirty adults with T2DM inadequately controlled by metformin (≥ 1000 mg/day) and sitagliptin (100 mg) were 1:1:1 randomised to receive DW1026C1 (E10 group, n = 77), DW1026C2 (E25 group, n = 76), or a placebo (n = 77). Treatment was administered for 24 weeks, followed by a 28-week extension period. The primary endpoint was the change in HbA1c from baseline to Week 24. RESULTS: Baseline characteristics were similar among groups. At Week 24, both active treatments demonstrated statistically significant HbA1c reductions versus the placebo. The least square mean differences [95% CI] versus the placebo were -0.54% [-0.78, -0.29] for E10 group and -0.61% [-0.85, -0.36] for E25 group (both p < 0.0001). Fasting plasma glucose (FPG), insulin resistance, body weight, systolic blood pressure, albumin-creatinine ratio and high-density lipoprotein cholesterol also improved in the active groups. Reductions in HbA1c, FPG and insulin resistance were sustained in Week 52. Safety profiles were favourable with adverse events similar in frequency and no increased hypoglycaemia risk. CONCLUSION: Sitagliptin/empagliflozin FDC doses achieved improvements in glycaemic control at 24 weeks, which was maintained through 52 weeks. These benefits were accompanied by a favourable safety profile, including a very low risk of hypoglycaemia. TRIAL REGISTRATION: NCT07076056.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Changes in HbA1c and FPG (A) HbA1c, % at Weeks 12, 24, 38 and 52; (B) changes in HbA1c from baseline to Weeks 24 and 52; (C) change in HbA1c from baseline (≥ 8.0%) to Weeks 24 and 52; (D) changes in HbA1c from baseline (< 8.0%) to Weeks 24 and 52; (E) FPG, mg/dL at Weeks 12, 24, 38 and 52; (F) changes in FPG from baseline to Weeks 24 and 52; (G) achievement rate of target HbA1c < 7.0% at Weeks 12 and 24; (H) achievement rate of target HbA1c < 7.0% or reduction > 0.5% at Weeks 12 and 24. HbA1c and FPG values at each week are presented with mean and SD denoted with error bar. Changes from baseline are presented with LS mean ± SE for treatment period, and with mean ± SD for extension period. LS means and group comparisons during extension period based on changes were not performed due to treatment re‐randomisation of placebo group at Week 24. Within‐group change was analysed by paired t ‐test or Wilcoxon signed rank test. Changes were compared between groups using mixed effect model for repeated measures. Achievement rates of target HbA1c level were compared between groups by logistic regression. * p < 0.01; ** p < 0.001; *** p < 0.0001. p values for efficacy endpoints other than change in HbA1c at Week 24 are reported as nominal. CI, confidence interval; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LS mean, least squares mean; OR, odds ratio; SD, standard deviation; SE, standard error.
非 KM Figure
FIGURE 2Other glycaemic parameter and metabolic parameters. (A) Changes in HOMA‐IR from baseline to Weeks 12 and 24; (B) Changes in body weight from baseline to Weeks 12 and 24. (C) Changes in SBP from baseline to Weeks 12 and 24. (D) Changes in ACR from baseline to Weeks 12 and 24. (E) Changes in eGFR from baseline to Weeks 12 and 24. (F) Changes in eGFR from Week 24 to Weeks 38 and 52. Changes from baseline are presented with least squares mean ± standard error. Within‐group change was analysed by paired t‐test or Wilcoxon signed rank test. Changes were compared between groups using mixed effect model for repeated measures. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. All p values are reported as nominal. ACR, albumin‐creatinine ratio; eGFR, estimated glomerular filtration rate; HOMA‐IR, homeostasis model assessment of insulin resistance; SBP, systolic blood pressure.
非 KM Figure